NCT04524338 Longitudinal Study Examining At-Home tDCS
| NCT ID | NCT04524338 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lady Davis Institute |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2021-02-22 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2021-02-22 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Participants with dementia have reported improvements after receiving tDCS in a study at our lab. Although we make an effort to enroll such participants in further tDCS research studies, some participants are ineligible for further studies or simply unwilling to continue being a research participant. These same individuals, however, are interested in purchasing their own tDCS machine and have approached us for advice on how to purchase their own machine. Because these devices are commercially available, there is nothing theoretically stopping these participants from purchasing their own machine. Therefore, we have chosen to carry out a longitudinal study that will allow us to serve as an advisory role for participants who have decided to continue administering tDCS at home. We will recommend the tDCS related items that should be purchased, and train participants on how to properly administer tDCS. Monthly reports will also be collected, which will allow us to monitor the person's condition. We plan to monitor participants for at least two years. From these reports, we will be able determine to what extent tDCS is beneficial when done at home as a treatment for dementia symptoms.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Alzheimer's Disease or other form of dementia (e.g., Primary Progressive Aphasia) Exclusion Criteria: * Metal in the head or other factors that would make stimulation unsafe
Contact & Investigator
Carlos Roncero, PhD
PRINCIPAL INVESTIGATOR
Baycrest
Frequently Asked Questions
Who can join the NCT04524338 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 100 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04524338 currently recruiting?
Yes, NCT04524338 is actively recruiting participants. Contact the research team at shelley.solomon2@mail.mcgill.ca for enrollment information.
Where is the NCT04524338 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT04524338 clinical trial?
NCT04524338 is sponsored by Lady Davis Institute. The principal investigator is Carlos Roncero, PhD at Baycrest. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.